Biblio Discovery — Demo Discovery Service

6 results for "Akash Sabarwal"

Showing 1–6 · 0.21 seconds · RSS

  1. Journal Article

    Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities

    Akash Sabarwal; Saba Tabasum; Laxminarayan Rawat et al.

    Clinical and Translational Discovery, Vol. 5 No. 6 · 2025 · English · DOAJ Scopus

    Abstract CD70, a tightly regulated immune co‐stimulatory ligand under physiological conditions, becomes aberrantly and persistently overexpressed in a wide spectrum of malignancies, including renal cell carcinoma (RCC), glioblastoma and acute myeloid leukaemia. This tumour‐restricted expression…

  2. Journal Article

    A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress

    Laxminarayan Rawat; Murugabaskar Balan; Yuzuru Sasamoto et al.

    Redox Biology, Vol. 68 · 2023 · English · DOAJ Scopus

    Receptor tyrosine kinase (RTK), c-Met, is overexpressed and hyper active in renal cell carcinoma (RCC). Most of the therapeutic agents mediate cancer cell death through increased oxidative stress. Induction of c-Met in renal cancer cells promotes the activation of redox-sensitive transcription…

  3. Journal Article Full text

    Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells

    Yasaman Hamedani; Samik Chakraborty; Akash Sabarwal et al.

    PLOS ONE, Vol. 15 No. 12 · 2020 · English · PLOS Scopus

    Renal Cell Carcinoma (RCC) often becomes resistant to targeted therapies, and in addition, dose-dependent toxicities limit the effectiveness of therapeutic agents. Therefore, identifying novel drug delivery approaches to achieve optimal dosing of therapeutic agents can be beneficial in managing…

    Also available at: DOAJ

  4. Journal Article

    AXL signaling in cancer: from molecular insights to targeted therapies

    Monika Yadav; Akansha Sharma; Ketki Patne et al.

    Signal Transduction and Targeted Therapy, Vol. 10 No. 1 · 2025 · English · DOAJ Scopus

    Abstract AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in various tumor-promoting pathways, including cancer cell proliferation, invasion…